Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

BEACON-AA: Apixaban mit oder ohne Clopidogrel bei Schlaganfallpatienten mit Vorhofflimmern und zerebraler Atherosklerose

15. November 2026 aktualisiert von: Yonsei University

Eine multizentrische prospektive randomisierte Studie zur Bewertung der Wirksamkeit von Apixaban und Clopidogrel bei der Prävention von rezidivierendem ischämischem Schlaganfall bei Patienten mit Vorhofflimmern und zerebraler Atherosklerose

This trial aims to compare the safety and efficacy of apixaban alone versus apixaban combined with clopidogrel in patients with acute ischemic stroke associated with non-valvular atrial fibrillation and concomitant symptomatic intracranial or extracranial atherosclerosis or complex plaque in the ascending aorta or aortic arch (≥4 mm in thickness, mobile, or ulcerated). Participants will be randomly assigned in a 1:1 ratio to receive apixaban monotherapy or dual therapy with clopidogrel for 30 days. The primary outcome is the incidence of new symptomatic or asymptomatic ischemic lesions on DWI/FLAIR at 30 (±5) days compared with baseline MRI, adjudicated by a central committee.

Studienübersicht

Status

Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Although oral anticoagulants are effective in preventing cardioembolic stroke in patients with non-valvular atrial fibrillation (NVAF), a considerable proportion of ischemic strokes in these patients are caused by concomitant large artery atherosclerosis. Carotid or intracranial artery stenosis is present in a substantial number of patients with NVAF and is associated with a higher risk of recurrent cerebral infarction despite standard anticoagulation. In such patients, adding an antiplatelet agent to oral anticoagulation may theoretically reduce atherothrombotic events, but it also raises concern for increased bleeding risk. Recent clinical evidence on this issue remains limited, and the optimal antithrombotic strategy for patients with NVAF and coexisting symptomatic atherosclerotic stenosis has not been clearly established.

The BEACON-AA trial is a multicenter, randomized, open-label, blinded-endpoint (PROBE) study designed to compare the safety and efficacy of apixaban monotherapy versus apixaban combined with clopidogrel in patients with acute ischemic stroke associated with non-valvular atrial fibrillation (NVAF) and concomitant symptomatic intracranial or extracranial atherosclerosis or complex plaque in the ascending aorta or aortic arch (≥4 mm in thickness, mobile, or ulcerated). Participants will be randomized in a 1:1 ratio to receive apixaban alone or apixaban plus clopidogrel for 30 days, followed by apixaban monotherapy thereafter.

Brain MRI including diffusion-weighted and FLAIR sequences will be performed at baseline and at 30 ± 5 days to assess new or recurrent ischemic lesions. The primary efficacy outcome is the incidence of new symptomatic or asymptomatic ischemic lesions on DWI/FLAIR at 30(±5) days compared with baseline MRI, adjudicated by a central committee. Secondary efficacy outcomes include: 1) incidence of symptomatic ischemic stroke or transient ischemic attack within 90 days, 2) incidence of acute coronary syndrome within 90 days,3) cardiovascular mortality within 90 days, 4) composite major cardiovascular events within 90 days, 5) all-cause mortality within 90 days, 6) proportion of patients with modified Rankin Scale (mRS) 0-2 at 90 days, and 7) proportion of patients with mRS 0-3 at 90 days. The primary safety outcomes are: 1) incidence of major bleeding within 90 days, defined according to the International Society on Thrombosis and Haemostasis (ISTH) criteria and 2) incidence of new asymptomatic cerebral hemorrhages detected on brain MRI(MR-Diffusion/FLAIR/SWI (or GRE)) at 30 ± 5 days after randomization. All imaging and clinical events will be independently adjudicated by blinded central adjudication committees.

Studientyp

Interventionell

Einschreibung (Geschätzt)

586

Phase

  • Phase 4

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

  • Name: Young Dae Kim, M.D. Ph.D.
  • Telefonnummer: 02-2228-1619
  • E-Mail: NEURO05@YUHS.AC

Studienorte

      • Busan, Südkorea
        • Rekrutierung
        • Pusan National University Hospital
        • Kontakt:
      • Busan, Südkorea
        • Rekrutierung
        • Dong-A University Hospital
        • Kontakt:
      • Chuncheon, Südkorea
        • Rekrutierung
        • Hallym University Chuncheon Sacred Heart Hospital
        • Kontakt:
      • Daegu, Südkorea
        • Rekrutierung
        • Keimyung University Dongsan Hospital
        • Kontakt:
      • Goyang, Südkorea
        • Rekrutierung
        • National Health Insurance Service Ilsan Hospital
        • Kontakt:
      • Incheon, Südkorea
        • Rekrutierung
        • Inha University Hospital
        • Kontakt:
      • Incheon, Südkorea
        • Rekrutierung
        • Gachon University Gil Medical Center
        • Kontakt:
      • Incheon, Südkorea
        • Rekrutierung
        • Catholic Kwandong University International St. Mary's Hospital
        • Kontakt:
      • Seoul, Südkorea
        • Rekrutierung
        • Samsung Medical Center
        • Kontakt:
      • Seoul, Südkorea
        • Rekrutierung
        • Seoul National University Hospital
        • Kontakt:
          • Keun-Hwa Jung, Professor
          • Telefonnummer: +82-1588-5700
          • E-Mail: jungkh@gmail.com
      • Seoul, Südkorea
        • Rekrutierung
        • Korea University Anam Hospital
        • Kontakt:
      • Seoul, Südkorea
        • Rekrutierung
        • Kangbuk Samsung Hospital
        • Kontakt:
      • Seoul, Südkorea
        • Rekrutierung
        • Ewha Womans University Seoul Hospital
        • Kontakt:
      • Seoul, Südkorea
        • Rekrutierung
        • Gangnam Severance Hospital
        • Kontakt:
          • Yo Han Jung, Professor
          • Telefonnummer: +82-1599-6114
          • E-Mail: YHJUNG@yuhs.ac
      • Seoul, Südkorea
        • Rekrutierung
        • Hanyang University Seoul Hospital
        • Kontakt:
      • Seoul, Südkorea
        • Rekrutierung
        • Kyung Hee University Hospital
        • Kontakt:
      • Seoul, Südkorea
        • Rekrutierung
        • Kyung Hee University Hospital at Gangdong
        • Kontakt:
      • Seoul, Südkorea
        • Rekrutierung
        • Inje University Sanggye Paik Hospital
        • Kontakt:
      • Seoul, Südkorea
        • Rekrutierung
        • Kangdong Sacred Heart Hospital
        • Kontakt:
      • Seoul, Südkorea
        • Rekrutierung
        • Yonsei University College of Medicine
        • Kontakt:
          • Young Dae Kim, Professor
          • Telefonnummer: +82-2-2228-1619
          • E-Mail: NEURO05@YUHS.AC
      • Yŏngin, Südkorea
        • Rekrutierung
        • Yongin Severance Hospital
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

19 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. Adults aged 19 years or older at the time of enrollment.

  2. Patients with non-valvular atrial fibrillation (NVAF) documented by electrocardiography.

  3. Acute ischemic stroke confirmed by brain MRI (diffusion-weighted and FLAIR sequences), with last known well within 120 hours prior to randomization.

  4. Presence of clinically significant atherosclerosis in the cerebral or aortic arteries, meeting at least one of the following criteria:

    ① ≥30% stenosis in the relevant artery (the artery supplying the infarcted territory) demonstrated by CTA, MRA, or DSA - using the WASID criteria for intracranial arteries and NASCET criteria for extracranial arteries.

    ② High-risk atherosclerotic plaque features in the relevant artery demonstrated by CTA, MRA, or ultrasound, such as ulceration, intraplaque hemorrhage, mobile plaque, or a large lipid core (involving ≥25% of plaque cross-sectional area) on CTA/MRA, or ulceration, mobile plaque, or hypoechoic/echolucent plaque on ultrasound; or presence of branch artery occlusive disease (BAOD).

    ③ Complex aortic plaque (≥4 mm in thickness, mobile, or ulcerative) identified in the ascending aorta or aortic arch by transthoracic/transesophageal echocardiography or coronary CT angiography.

  5. Written informed consent provided by the participant or a legally authorized representative.

Exclusion Criteria:

  1. Presence of mechanical heart valves or rheumatic mitral stenosis.
  2. Requirement for antithrombotic agents other than apixaban and clopidogrel.
  3. Planned percutaneous coronary intervention, coronary artery bypass graft surgery, carotid endarterectomy, or intracranial stenting within 3 months after enrollment.
  4. Presence of mural thrombus in the heart confirmed by imaging.
  5. Renal impairment with creatinine clearance ≤25 mL/min.
  6. Severe hepatic impairment, including acute hepatitis, chronic active hepatitis, hepatic lesions or coagulopathy, hepatic failure, or laboratory evidence of AST/ALT >2× the upper limit of normal (ULN) or total bilirubin ≥1.5× ULN.
  7. Small-vessel occlusion (lacunar infarction) according to the TOAST classification.
  8. History within the past 30 days of gastrointestinal bleeding, vascular malformation of the brain or spinal cord, recent brain, spinal, or ophthalmologic surgery or trauma, esophageal varices, or intracranial hemorrhage at any time; or chronic regular use of NSAIDs (≥3 days per week for ≥2 consecutive weeks).
  9. Ischemic stroke occurring despite concurrent use of both NOAC and antiplatelet therapy.
  10. Planned surgery or high-bleeding-risk procedure within 3 months, or presence of active bleeding at enrollment.
  11. Anemia (hemoglobin < 8.0 g/dL) or thrombocytopenia (platelet count < 100,000/µL).
  12. Pre-stroke modified Rankin Scale (mRS) ≥ 2.
  13. Severe comorbid illness or malignancy not in complete remission with an expected life expectancy <1 year.
  14. Known hypersensitivity or allergy to apixaban or clopidogrel.
  15. Pregnant or breastfeeding women.
  16. Uncontrolled diabetes mellitus (HbA1c > 10.0%) or severe hypertension (systolic ≥ 220 mmHg or diastolic ≥ 120 mmHg).
  17. Concomitant use of strong CYP3A4 and P-glycoprotein inhibitors that can significantly increase apixaban exposure (e.g., ketoconazole, itraconazole, ritonavir, clarithromycin).
  18. Concomitant use of strong CYP2C19 inducers that can enhance clopidogrel antiplatelet effect and increase bleeding risk (e.g., rifampin, carbamazepine, phenytoin, phenobarbital, St. John's wort).
  19. Clinically significant mass effect due to space-occupying cerebral infarction, or patients expected to require decompressive craniectomy, including those with midline shift > 5 mm, loss of basal cisterns, herniation, fourth-ventricle compression, or obstructive hydrocephalus in posterior fossa infarcts.
  20. Intracranial hemorrhage or hemorrhagic transformation (PH1 or PH2) according to ECASS criteria.
  21. Participation in another interventional clinical trial within the past 30 days or concurrent participation in another interventional study (non-interventional observational or registry studies may be allowed at the investigator's discretion).
  22. Any other condition that, in the investigator's judgment, would make participation or continued involvement in the study inappropriate or infeasible.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Verhütung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Single

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Apixaban and Clopidogrel Combination Therapy

Participants receive apixaban(5mg twice daily, or 2.5mg twice daily if indicated) plus clopidogrel 75mg daily for 30days, followed by apixaban monotherapy thereafter.

Apixaban 5mg(or 2.5mg if indicated) twice daily. Used as monotherapy or in combination with clopidogrel for 30 days, then continued as monotherapy.

Andere Namen:
  • Eliquis

Clopidogrel 75mg once daily for 30 days in combination with apixaban, then discontinued.

Andere Namen:
  • Plavix
Aktiver Komparator: Apixaban Monotherapy

Participants receive apixaban 5mg(or 2.5mg if indicated) twice daily as monotherapy for 30 days and continue apixaban monotherapy thereafter.

Apixaban 5mg(or 2.5mg if indicated) twice daily. Used as monotherapy or in combination with clopidogrel for 30 days, then continued as monotherapy.

Andere Namen:
  • Eliquis

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Incidence of new symptomatic or asymptomatic ischemic lesions on DWI/FLAIR at 30(±5) days compared with baseline MRI, adjudicated by a central committee
Zeitfenster: At 30 ± 5 days after randomization

New ischemic lesions, either symptomatic or asymptomatic, identified on DWI/FLAIR at 30 (±5) days compared with baseline MRI, as adjudicated by a central adjudication committee.

At 30 ± 5 days after randomization

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Incidence of symptomatic ischemic stroke or transient ischemic attack (TIA)
Zeitfenster: Within 90 days after randomization

Occurrence of new symptomatic ischemic stroke or transient ischemic attack confirmed by clinical and/or imaging criteria.

Within 90 days after randomization
Incidence of acute coronary syndrome (ACS)
Zeitfenster: Within 90 days after randomization

Occurrence of acute coronary syndrome, including unstable angina or myocardial infarction, confirmed by standard diagnostic criteria.

Within 90 days after randomization
Cardiovascular mortality
Zeitfenster: Within 90 days after randomization

Death due to fatal stroke, fatal myocardial infarction, or sudden death not clearly attributed to non-vascular causes.

Within 90 days after randomization
Composite major cardiovascular events
Zeitfenster: Within 90 days after randomization

Composite of recurrent stroke (ischemic or hemorrhagic), acute coronary syndrome, or cardiovascular death.

Within 90 days after randomization
All-cause mortality
Zeitfenster: Within 90 days after randomization

Death from any cause during the 90-day follow-up period.

Within 90 days after randomization
Proportion of patients with modified Rankin Scale (mRS) score 0-2
Zeitfenster: At 90 days after randomization

Functional independence defined as mRS score of 0-2 at day 90.

At 90 days after randomization
Proportion of patients with modified Rankin Scale (mRS) score 0-3
Zeitfenster: At 90 days after randomization

Favorable functional outcome defined as mRS score of 0-3 at day 90.

At 90 days after randomization
Incidence of major bleeding events according to the ISTH criteria
Zeitfenster: Within 90 days after randomization

Major bleeding events defined by the International Society on Thrombosis and Haemostasis (ISTH) criteria, including fatal bleeding, symptomatic intracranial hemorrhage, intraocular bleeding causing vision loss, bleeding resulting in inability to perform usual activities, bleeding requiring transfusion of ≥2 units of whole blood or red cells, or bleeding leading to hospitalization.

Within 90 days after randomization
Incidence of new asymptomatic cerebral hemorrhages detected on brain MRI(MR-Diffusion/FLAIR/SWI (or GRE))
Zeitfenster: At 30 ± 5 days after randomization

Newly developed asymptomatic cerebral hemorrhages identified on MR-Diffusion/FLAIR/SWI(or GRE) performed 30 ± 5 days after randomization.

At 30 ± 5 days after randomization

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

14. Juli 2026

Primärer Abschluss (Geschätzt)

1. Juli 2029

Studienabschluss (Geschätzt)

31. August 2029

Studienanmeldedaten

Zuerst eingereicht

14. November 2025

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

14. November 2025

Zuerst gepostet (Tatsächlich)

19. November 2025

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

18. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

15. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

UNENTSCHIEDEN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .